Reach Us +44-1904-929220
Identifying Role Of N-myristoyltransferase In The MTOR Signalling Cascade Of ER-α Positive Breast Cancer Cells (MCF-7) | 8924

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Identifying role of N-myristoyltransferase in the mTOR signalling cascade of ER-α positive breast cancer cells (MCF-7)

4th International Conference on Biomarkers & Clinical Research

Danira Jaksic, Andrew McQuiggin, Leigh Murphy and Anuraag Shrivastav

Posters: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.018

B reast cancer is the most common malignancy in women from the western world. Estrogen receptor (ER) is a key regulatory in the malignancy of breast cancer. The status of the ER-α of breast tumours is used for predicting response to endocrine therapy. ER-α can be post-translationally modified multiple ways including but not limited to phosphorylation, acylation and, ubiquitination. ER- α can be phosphorylated on multiple amino acid residues throughout the whole protein and within all major structural domains: the N-terminal A/B domain, the DNA-binding or C domain, the hinge or D domain and, the ligand-binding domain or E domain. When phosphorylation occurs in the N-terminal domain it is associated with good endocrine therapy outcome, while phosphorylation that occurs in the C-terminal domain leads to poor prognosis. For example, phosphorylation of the ER-α at S 118 , S 167 , and S 236 predict better prognosis whereas, T 311 , Y 537 , and S 559 predict poor outcome. This has lead to a phosphorylation score called P7 score that more precisely predicts prognosis. Independent studies suggest ER- α phosphorylated at serine 118 leads to good endocrine therapy prognosis while phosphorylation at tyrosine 537 leads to poor outcome. N- myristoyltransferase (NMT) is an enzyme that modifies proteins by covalently attaching a myristic acid to their N-terminal end. The non-receptor tyrosine kinase pp60cSrc phosphorylates ER- α at tyrosine 537 leading to poor prognosis. Myristoylation of pp60cSrc is essential for its activation. The mTOR pathway member Akt/PKB regulates NMT1 activity thus establishing a crosstalk between mTOR pathway and NMT mediated signalling pathways. Therefore, we investigated mTOR- NMT-cSrc mediated regulation of ER-α in ER-α positive MCF-7 cells by inhibiting mTOR and ER-α. Results suggest increased expression of NMT1 upon down-regulating mTORC1 activity and further activation of NMT mediated signalling pathway such as activation of c-Src. Understanding of ER-α activation mechanism would lead to identification of panel of surrogate markers, which would aid in designing treatment protocols for better endocrine therapy outcomes
Relevant Topics